Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Lymphoma, Large B-Cell, Diffuse 5Lymphoma, Follicular 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, Mantle-Cell 3Leukemia, Lymphocytic, Chronic, B-Cell 3Leukemia 3Waldenstrom Macroglobulinemia 2Melanoma 2Lymphoma, Non-Hodgkin 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Myeloid, Acute 2Burkitt Lymphoma 2Unspecified Adult Solid Tumor, Protocol Specific 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma 1Lung Neoplasms 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Intraocular Lymphoma 1Hodgkin Disease 1Gastrointestinal Stromal Tumors 1Extensive Stage Small Cell Lung Cancer 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1

Interventions

Imatinib Mesylate 8Specimen Handling 2Oxaliplatin 2Magnetic Resonance Spectroscopy 2Ipilimumab 2CTLA-4 Antigen 2temsirolimus 1rubitecan 1romidepsin 1oblimersen 1motexafin lutetium 1guadecitabine 1alvocidib 1Sorafenib 1Sirolimus 1Semaxinib 1Rogaratinib 1Nivolumab 1Leucovorin 1Irinotecan 1Immunoglobulin G 1HhAntag691 1Floxuridine 1Erlotinib Hydrochloride 1Doxorubicin 1Disulfides 1Dasatinib 1Cetuximab 1Biopsy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Gastrointestinal Stromal Tumors × oblimersen × Clear all
NCT00091078 2013-06-05

Oblimersen and Imatinib Mesylate in Treating Patients With Advanced Gastrointestinal Stromal Tumors That Cannot Be Removed By Surgery

National Cancer Institute (NCI)

Phase 2 Terminated
96 enrolled
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡